Redwood City, CA – June 3, 2008 – Ingenuity Systems, the leading provider of information solutions for life science researchers, announced the signing of a four year agreement with Boehringer Ingelheim for Ingenuity Pathway Analysis (IPA). IPA will be used throughout the Boehringer Ingelheim research and development organization to unlock novel insights from experimental data and as a general tool for biological search and exploration.
The agreement provides global access for Boehringer Ingelheim research scientists to access to the recently released IPA 6, which includes new biological and chemical content, in addition to Path Designer, an award-winning set of tools that more clearly communicates information about networks and pathways.
“We are pleased at this opportunity to become a strategic partner in Boehringer Ingelheim’s research and development efforts,” stated Jake Leschly, CEO, Ingenuity Systems.
About Ingenuity Systems®
Ingenuity Systems is a leading provider of information solutions for the exploration, interpretation, and analysis of life science information. All of Ingenuity’s products and services have one common goal – to help life science researchers generate maximum value from all types of biological and chemical knowledge. Ingenuity offers a broad and flexible range of solutions that can be tailored to needs of various clients, including academic and therapeutic area researchers, computational biologists and informatics departments, and suppliers in the life sciences industry.
IPA is an all-in-one software application that enables researchers to model, analyze, and understand the complex biological and chemical systems at the core of life science research. IPA’s search capabilities provide users with access to the highest quality detail-rich knowledge available on genes, drugs, chemicals, protein families, cellular and disease processes, and signaling and metabolic pathways. IPA supports analysis of data from all experimental platforms, and is used at all stages of the drug discovery and development process, including target identification and validation, biomarker discovery, molecular toxicology, metabolomics, and pharmacogenomics. IPA has been broadly adopted and cited in hundreds of peer-reviewed journals.
All of the products leverage Ingenuity’s knowledge base, the largest data base of its kind, which houses the biological and chemical relationships extracted from scientific literature. The information is uniquely structured so scientists can ask complex biological questions to gain rapid insight into their experimental data or create relevant biological models to move forward in their research. Today, Ingenuity’s solutions are used by thousands of researchers at hundreds of leading pharmaceutical, biotechnology, and academic research institutions worldwide. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, Australia, and Japan. www.ingenuity.com.